{"tid":177378,"cid":5,"subCid":0,"title":"全球首例 日本完成iPS細胞他體移植","createTime":"2017-03-28T21:48:56.000Z","updateTime":"2017-03-29T14:50:25.000Z","uid":22675,"like":3,"dislike":0,"uniUserReply":0,"replies":[{"pid":"40e36bc510a22ac5f647cebf4fae3168cc762f3e","tid":177378,"uid":22675,"like":0,"dislike":0,"score":0,"citedBy":0,"replyTime":"2017-03-28T21:48:56.000Z","msg":"<img src=\"https://na.cx/i/9NmED4f.jpg\" data-thumbnail-src=\"https://i.lih.kg/thumbnail?u=https%3A%2F%2Fna.cx%2Fi%2F9NmED4f.jpg&h=f4bfd544&s={SIZE}\" /><br />\n2017-03-29  01:28<br />\n中央社〕日本理化學研究所等團隊28日宣布，已實施由他人誘導性多功能幹細胞（iPS細胞）製作的視網膜細胞，移植至眼疾患者眼部的手術，這是iPS細胞所製作細胞的他體移植全球首例。<br />\n共同社報導，相較於使用患者本身iPS細胞的自體移植，優點是準備時間短、費用也較低。這是使用iPS細胞的日本再生醫療，邁向普及跨出的一大步。<br />\n理研的計畫負責人高橋政代等在神戶市立醫療中心中央市民醫院作為臨床研究，將含有由iPS細胞製作的視網膜細胞的溶液，以注射方式注入罹患滲出型老年性黃斑部病變的60多歲男性的眼部，該病症使視網膜出現障礙，甚至可能失明。手術約1小時後結束，過程順利。<br />\n手術的首要目的是確認安全性，研究團隊將檢驗移植後細胞是否會變成腫瘤，觀察能否維持視力。移植他人細胞的他體移植，有發生排斥反應的疑慮，但此次使用的iPS細胞是京都大學所儲備的特殊免疫型細胞，不容易發生排斥反應，將確認其有效性。<br />\n高橋表示，為觀察症狀預計將在2、3年後發佈移植是否成功等結果。<br />\n高橋等2014年實施了由患者自身iPS細胞製作視網膜細胞的自體移植手術。患者視力停止下降，手術後已2年，未發現癌變等異常，然而到移植為止共花費了11個月，費用高達約1億日圓，邁向普及還需縮短準備期間以及降低成本。<br />\n本次手術從2月初為臨床研究招募患者開始，僅約2個月就實現。包括本次患者在內，今後的目標是完成5例移植。<br />\n日本放送協會（NHK）報導，此次使用的iPS細胞是京都大學山中伸彌教授等製作的不易引發排斥反應的特殊iPS細胞，冷凍保存的這種特殊免疫型iPS細胞，除不易引發排斥反應，解凍後進行培養，幾乎可無限增殖。如果移植成功，每人約1億日圓的iPS細胞治療成本，可望降至1/10左右。<br />\n<br />\n<a href=\"http://news.ltn.com.tw/news/world/breakingnews/2019546\" data-sr-url=\"https://r.lihkg.com/link?u=http%3A%2F%2Fnews.ltn.com.tw%2Fnews%2Fworld%2Fbreakingnews%2F2019546&d=dMuVdPjJf30Qxtl2jkPsRIsQCuff2cTRbXvS6e969MQ%3D&h=474c563d\" data-ef-url=\"https://embed.lih.kg/frame?u=http%3A%2F%2Fnews.ltn.com.tw%2Fnews%2Fworld%2Fbreakingnews%2F2019546&h=539a1f83\" target=\"_blank\">http://news.ltn.com.tw/news/world/breakingnews/2019546</a>"},{"pid":"45fe368136e96d0f11dc9e3b9edaa483c78e0bb3","tid":177378,"uid":23277,"like":0,"dislike":0,"score":0,"citedBy":0,"replyTime":"2017-03-28T22:26:20.000Z","msg":"控制得唔好生tumour唔係無可能<img src=\"/assets/faces/lomoji/18.png\" class=\"hkgmoji\" />"},{"pid":"c2b1fe91ca7def001426cc59b2613f689532f9f6","tid":177378,"uid":73262,"like":0,"dislike":0,"score":0,"citedBy":0,"replyTime":"2017-03-29T00:27:56.000Z","msg":"日本果然係亞洲最優秀人種"},{"pid":"10cbdb1ecda5035a643ae16499b9e5d5218e0078","tid":177378,"uid":52215,"like":0,"dislike":0,"score":0,"citedBy":0,"replyTime":"2017-03-29T00:30:31.000Z","msg":"iPS<img src=\"/assets/faces/normal/dead.gif\" class=\"hkgmoji\" /><br />\nAmoled<img src=\"/assets/faces/normal/agree.gif\" class=\"hkgmoji\" />"},{"pid":"3ec61cdeb07f102617ecaa79f437b90eb9901c36","tid":177378,"uid":37528,"like":0,"dislike":0,"score":0,"citedBy":0,"replyTime":"2017-03-29T00:46:51.000Z","msg":"Doctor X<img src=\"/assets/faces/normal/agree.gif\" class=\"hkgmoji\" /><img src=\"/assets/faces/normal/agree.gif\" class=\"hkgmoji\" />"},{"pid":"a6c94b5ba0c989698c1b199574c52fa61303df13","tid":177378,"uid":91422,"like":0,"dislike":0,"score":0,"citedBy":0,"replyTime":"2017-03-29T00:56:11.000Z","msg":"iPS,係以幾個基因令到普通細胞變返做幹細胞。咁幹細胞就可以分裂做唔同組織或者器官。"},{"pid":"b4bc05d27e8c65b79937be61878512d4dd0e9814","tid":177378,"uid":22675,"like":0,"dislike":0,"score":0,"citedBy":0,"replyTime":"2017-03-29T10:50:21.000Z","msg":"<img src=\"/assets/faces/normal/hoho.gif\" class=\"hkgmoji\" />"},{"pid":"a238956cefdca8ad96a1df9972d791e478be92a7","tid":177378,"uid":38523,"like":0,"dislike":0,"score":0,"citedBy":0,"replyTime":"2017-03-29T11:28:03.000Z","msg":"支那呢？"},{"pid":"d2e3a339af9149f18b838412542c244b23f7c884","tid":177378,"uid":25424,"like":0,"dislike":0,"score":0,"citedBy":0,"replyTime":"2017-03-29T14:50:25.000Z","msg":"<blockquote>支那呢？</blockquote><br />\n活摘<img src=\"/assets/faces/normal/agree.gif\" class=\"hkgmoji\" />"}]}